Differential Expression of FGFRs Signaling Pathway Components in Bladder Cancer: A Step Toward Personalized Medicine.

Variations Improper activation and inappropriate expression of fibroblast growth factor receptors () in cancer suggests that they can act as therapeutic targets. Fibroblast growth factor receptor inhibitors are currently employed in clinical trials of different cancers. Regarding the essence and the importance of the personalized medicine, mainly mirrored by remarkable inter-individual variations in different populations, we aimed to perform a pilot study to address and expression levels and their correlation with the clinicopathological features in Iranian patients with bladder cancer (BC). Paired tumor and adjacent non tumor tissue samples along with their clinico-pathological parameters were obtained from 50 cases diagnosed with BC in different stages and grades. The mRNA expressions of and in tissue samples were determined by real-time polymerase chain reaction (real-time PCR). The expression levels of were significantly higher in tumor tissues when compared to adjacent normal tissues ( = 0.007), regardless of the stages and grades of the tumor. Over expression was associated with cigarette smoking ( = 0.037) and family history for cancer ( = 0.004). Decreased expression of was observed, remarkably evident in high-grade tumors ( = 0.047), while over expression was detected in low-grade samples. This pilot study clearly suggests that in Iranian BC patients and expression patterns are different, and also highly distinctive with regard to the tumor's stage and grade. Such particular expression patterns may indicate their special values to be employed for interventional studies aiming targeted therapy. Further studies with a larger sample size are needed to validate our results.